Device Trial Radar · NCT05535361
A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome
Last checked: Nov 20, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Sep 15, 2023
Primary completion
Mar 1, 2028
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- Eclipse Regenesis, Inc.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Children's Hospital Medical Center, Cincinnati; University of California, San Francisco; Boston Children's Hospital; Lucile Packard Children's Hospital at Stanford; Children's National Health System, Washington DC
- First posted
- Sep 10, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 3 months, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients with Short Bowel Syndrome
Conditions
- Short Bowel Syndrome
Interventions
Distraction Enterogenesis in Adult Patients with Short Bowel SyndromeDevice
The surgeon verifies the intestinal diameter and selects the appropriate device diameter size. The device is introduced into the lumen of the intestine and advanced about 5-10cm. The surgeon uses 4-0 chromic sutures placed in the seromuscular layer to secure the XL1 Coil within the intestine. The surgeon places metal clips on proximal and distal sutures and in the mesentery adjacent to the XL1 Coil ends to mark the location for radiologic evaluation. The surgeon releases the XL1 Coil and closes the enterotomy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Device and procedure related adverse eventsTime frame: 4 to 6 months
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Lucile Packard Children's Hospital Stanford
Palo Alto, California · Recruiting
4 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.